$0013

Generating a unique summary for 0013.HK…

AI-generated for information only — not investment advice.

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Institutions hold 19.33% · insiders 38.80% · 105 institutions

No institutional filings available for this ticker.

No insider transactions reported.

Consensus score 1.38 (1 = strong buy, 5 = sell) · mean target 31.46

No recent analyst actions.

Next report: 2026-07-30

No earnings history available.

No filings indexed for this ticker.

• HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

  HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr

  Thu, 03 Sep 2026 17:02:29 +0000

• Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

  Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to...

  Thu, 03 Sep 2026 09:30:00 +0000

• HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

  Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. HUTCHMED will receive US$110 million upfront and...

  Thu, 03 Sep 2026 07:27:00 +0000

• HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

  — Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English — HONG KONG and FLORHAM PARK, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered in

  Thu, 03 Sep 2026 04:00:00 +0000

• HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

  Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line settingHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”

  Mon, 31 Aug 2026 00:00:00 +0000

• HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

  Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in ChinaHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical P

  Fri, 28 Aug 2026 00:00:00 +0000

• HUTCHMED shares rise as lung cancer drug trial hits key targets

  Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in...

  Mon, 17 Aug 2026 14:37:00 +0000

• HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

  — First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) de

  Mon, 17 Aug 2026 00:00:00 +0000